Ruf P - Search Results

1

Two new trifunctional antibodies for the therapy of human malignant melanoma.

Ruf P, Jäger M, Ellwart J, Wosch S, Kusterer E, Lindhofer H. Ruf P, et al. Int J Cancer. 2004 Feb 20;108(5):725-32. doi: 10.1002/ijc.11630. Int J Cancer. 2004. PMID: 14696099

2

Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody.

Ruf P, Lindhofer H. Ruf P, et al. Blood. 2001 Oct 15;98(8):2526-34. doi: 10.1182/blood.v98.8.2526. Blood. 2001. PMID: 11588051

3

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer.

Ruf P, Gires O, Jäger M, Fellinger K, Atz J, Lindhofer H. Ruf P, et al. Br J Cancer. 2007 Aug 6;97(3):315-21. doi: 10.1038/sj.bjc.6603881. Epub 2007 Jul 10. Br J Cancer. 2007. PMID: 17622246 Free PMC article.

4

Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody.

Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Ruf P, Slavin S. Morecki S, et al. Among authors: ruf p. Exp Hematol. 2008 Aug;36(8):997-1003. doi: 10.1016/j.exphem.2008.03.005. Epub 2008 May 20. Exp Hematol. 2008. PMID: 18495330

5

Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels.

Stanglmaier M, Faltin M, Ruf P, Bodenhausen A, Schröder P, Lindhofer H. Stanglmaier M, et al. Among authors: ruf p. Int J Cancer. 2008 Sep 1;123(5):1181-9. doi: 10.1002/ijc.23626. Int J Cancer. 2008. PMID: 18546289

6

The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2.

Jäger M, Schoberth A, Ruf P, Hess J, Lindhofer H. Jäger M, et al. Among authors: ruf p. Cancer Res. 2009 May 15;69(10):4270-6. doi: 10.1158/0008-5472.CAN-08-2861. Epub 2009 May 12. Cancer Res. 2009. PMID: 19435924

7

Structural and functional characterization of the trifunctional antibody catumaxomab.

Chelius D, Ruf P, Gruber P, Plöscher M, Liedtke R, Gansberger E, Hess J, Wasiliu M, Lindhofer H. Chelius D, et al. Among authors: ruf p. MAbs. 2010 May-Jun;2(3):309-19. doi: 10.4161/mabs.2.3.11791. Epub 2010 May 16. MAbs. 2010. PMID: 20418662 Free PMC article.

8

Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients.

Ruf P, Kluge M, Jäger M, Burges A, Volovat C, Heiss MM, Hess J, Wimberger P, Brandt B, Lindhofer H. Ruf P, et al. Br J Clin Pharmacol. 2010 Jun;69(6):617-25. doi: 10.1111/j.1365-2125.2010.03635.x. Br J Clin Pharmacol. 2010. PMID: 20565453 Free PMC article. Clinical Trial.

9

Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3).

Jäger M, Schoberth A, Ruf P, Hess J, Hennig M, Schmalfeldt B, Wimberger P, Ströhlein M, Theissen B, Heiss MM, Lindhofer H. Jäger M, et al. Among authors: ruf p. Cancer Res. 2012 Jan 1;72(1):24-32. doi: 10.1158/0008-5472.CAN-11-2235. Epub 2011 Nov 1. Cancer Res. 2012. PMID: 22044753 Clinical Trial.

10

Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity.

Hess J, Ruf P, Lindhofer H. Hess J, et al. Among authors: ruf p. Future Oncol. 2012 Jan;8(1):73-85. doi: 10.2217/fon.11.138. Future Oncol. 2012. PMID: 22149036 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results